Daniyah M. Alkhawtani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniyah M. Alkhawtani has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Asmaa F. Khafaga
King Faisal University
1 shared publication - Badreldin M. Ahmed
Department of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11362, Saudi Arabia
1 shared publication - Khaled A. Alhumaidh
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kalamoon University, Damascus 222, Syria
1 shared publication - Mohamed Ezzat Abd El-Hack
Zagazig University
1 shared publication - Mohamed Farouk Elsadek
Department of Biochemistry, College of Sciences, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Nahla H. El-Shaer
Department of Zoology, Faculty of Science, Zagazig University, Zagazig 44511, Egypt
1 shared publication
Latest Publications
- Open Access
Thymoquinone-PLGA-PVA Nanoparticles Ameliorate Bleomycin-Induced Pulmonary Fibrosis in Rats via Regulation of Inflammatory Cytokines and iNOS Signaling
Pulmonary fibrosis is considered one of the most chronic interstitial illnesses which are not easily treated. thymoquinone’s (TQ) benefits are still partly problematic due to poor water solubility; therefore, it was loaded onto PLGA-PVA carriers. This study aimed to evaluate the potential effect of TQ-PLGA-PVA nanoparticles (TQ-PLGA-PVA-NPs) on pulmonary fibrosis induced by bleomycin in albino rats. Forty male rats were randomized into four groups. The first group served as the control group; the second and the third groups received bleomycin intratracheally, whereas the third group received TQ-PLGA-PVA-NPs after 4 weeks from bleomycin administration. The fourth group was administrated TQ-PLGA-PVA-NPs alone. The designed nanoparticles appeared around 20 nm size (10–30 nm), had a spherical shape, and had 80% encapsulation efficiency. The histological examination of rats simultaneously treated with TQ-PLGA-PVA-NPs and bleomycin revealed reduction in the thickness of the alveolar septa and improvement of the other lung structures, with the presence of lymphocytes admixed with exfoliated epithelium in a few lumina remaining. Ultrastructural findings revealed marked collagenolysis and the release of nanoparticles from ruptured pneumocytes within the alveolar septa after 14 days from TQ-PLGA-PVA-NPs administration. Very active pneumocyte types II were seen in the TQ-PLGA-PVANP group. Additionally, immunohistochemical expression of inducible nitric oxide (iNOS) and estimation of inflammatory cytokines in lung tissues including interleukin 10 (IL 10) and transforming growth factor-beta (TGF-β1) confirmed the antioxidant and anti-inflammatory effects of TQ-PLGA-PVANPs. The study concluded that TQ-PLGA-PVA-NPs could attenuate the bleomycin-induced pulmonary fibrosis, through the inhibition of lung inflammation and the suppression of bleomycin- induced oxidative stress.
Open AccessThymoquinone-PLGA-PVA Nanoparticles Ameliorate Bleomycin-Induced Pulmonary Fibrosis in Rats via Regulation of Inflammatory Cytokines and iNOS Signaling
Pulmonary fibrosis is considered one of the most chronic interstitial illnesses which are not easily treated. thymoquinone’s (TQ) benefits are still partly problematic due to poor water solubility; therefore, it was loaded onto PLGA-PVA carriers. This study aimed to evaluate the potential effect of TQ-PLGA-PVA nanoparticles (TQ-PLGA-PVA-NPs) on pulmonary fibrosis induced by bleomycin in albino rats. Forty male rats were randomized into four groups. The first group served as the control group; the second and the third groups received bleomycin intratracheally, whereas the third group received TQ-PLGA-PVA-NPs after 4 weeks from bleomycin administration. The fourth group was administrated TQ-PLGA-PVA-NPs alone. The designed nanoparticles appeared around 20 nm size (10–30 nm), had a spherical shape, and had 80% encapsulation efficiency. The histological examination of rats simultaneously treated with TQ-PLGA-PVA-NPs and bleomycin revealed reduction in the thickness of the alveolar septa and improvement of the other lung structures, with the presence of lymphocytes admixed with exfoliated epithelium in a few lumina remaining. Ultrastructural findings revealed marked collagenolysis and the release of nanoparticles from ruptured pneumocytes within the alveolar septa after 14 days from TQ-PLGA-PVA-NPs administration. Very active pneumocyte types II were seen in the TQ-PLGA-PVANP group. Additionally, immunohistochemical expression of inducible nitric oxide (iNOS) and estimation of inflammatory cytokines in lung tissues including interleukin 10 (IL 10) and transforming growth factor-beta (TGF-β1) confirmed the antioxidant and anti-inflammatory effects of TQ-PLGA-PVANPs. The study concluded that TQ-PLGA-PVA-NPs could attenuate the bleomycin-induced pulmonary fibrosis, through the inhibition of lung inflammation and the suppression of bleomycin- induced oxidative stress.
- Open Access
- 19 June 2017
- Published by MedCrave Group Kft. in Advances in Obesity, Weight Management & Control
- Vol. 6 (6) , 1-4
Assessment of Vitamin B12 Status in Patients with Morbid Obesity
Vitamin B12 (VB12) is an essential water-soluble vitamin that also known as Cobalamin. The various forms of cobalamin include cyanocobalamin, hydroxycobalamin, methyl cobalamin and 5-deoxyadenosylcobalamin.It has vital functions of human body include; DNA synthesis, folate metabolism, optimal haemopoiesis, neurological function. Dietary deficiency of VB12 is rare, except in elderly people and long-term vegans. Nutritional deficiency, malabsorption syndromes, and gastrointestinal disorder are the most common causes of VB12 deficiency. Recently, studies documented that there is a deficiency of VB12 and folic acid in obese people compared with normal BMI controls. This review was aimed to evaluate VB12 level among patients with morbid obesity. The current data concluded that there is negative correlation between VB12 and body mass index. For that reason, VB12 must be routinely tested in morbidly obese people.
- 19 June 2017
- Published by MedCrave Group Kft. in Advances in Obesity, Weight Management & Control
- Vol. 6 (6) , 1-4
Open AccessAssessment of Vitamin B12 Status in Patients with Morbid Obesity
Vitamin B12 (VB12) is an essential water-soluble vitamin that also known as Cobalamin. The various forms of cobalamin include cyanocobalamin, hydroxycobalamin, methyl cobalamin and 5-deoxyadenosylcobalamin.It has vital functions of human body include; DNA synthesis, folate metabolism, optimal haemopoiesis, neurological function. Dietary deficiency of VB12 is rare, except in elderly people and long-term vegans. Nutritional deficiency, malabsorption syndromes, and gastrointestinal disorder are the most common causes of VB12 deficiency. Recently, studies documented that there is a deficiency of VB12 and folic acid in obese people compared with normal BMI controls. This review was aimed to evaluate VB12 level among patients with morbid obesity. The current data concluded that there is negative correlation between VB12 and body mass index. For that reason, VB12 must be routinely tested in morbidly obese people.